HealthCapital Newsletter April 2022
HealthCapital Newsletter April 2022 If this newsletter is not displayed properly, please click here. Land Brandenburg und be Berlin
load images
HealthCapital Newsletter 2022

Dear Sir or Madam,

In these geopolitically very fraught times, many of us are aware of the importance of free trade relationships and reliable international cooperation! This is particularly true of the healthcare industry in Berlin and Brandenburg. We invite you to work together with us on the medicine of tomorrow!

Many players in the life science location of Berlin-Brandenburg are globally-minded. ProBioGen and MiGenTra are focusing on the African region and Middle East with their products in the area of biosimilars as well as cell and gene therapies. GrOwnvalve is using the EU funding it successfully acquired to develop the heart valves of the future, which could be a worldwide gamechanger. And the company Cellbricks even sees space as a future area of application for its 3D-printed wound closure developed in collaboration with the Berlin Institute of Health. We introduce these players to you in our interviews.

The BIONNALE will once again provide an in-depth insight into the plethora of exciting projects in the Berlin region in a few days. The world is invited to Berlin on 11 and 12 May 2022: the more than 1,000 people from almost 50 countries who will once again be taking part in the BIONNALE are looking forward to the opportunity to exchange ideas on site in Berlin or on the online platform. Let’s take a look at the future together!

Your
Dr. Kai Uwe Bindseil
Clustermanager HealthCapital Berlin-Brandenburg

 
     


    Focus Topics


    Interview with Jasper Emeis, research associate of the GrOwnValve project

    GrownValve is a spin-off of the Deutsches Herzzentrum Berlin and Charité. The company was founded in 2019. It develops patient-specific, endogenous heart valves, with a focus on pediatrics. We interview Jasper Emeis, research associate of GrOwnValve about the prosthetic heart valve developed by the company as well as the company’s future.

    Read more...

    Interview with Dr. Lutz Hilbrich, Chief Executive Officer at ProBioGen (and the subsidiary MiGenTra) and Andrea Hauptmann, Chief Financial Officer at ProBioGen (and the subsidiary MiGenTra)

    ProBioGen was founded in Berlin in 1994, and has been part of the Egyptian Minapharm Group since 2010. The biotech company and its subsidiary MiGenTra operate around the globe and have years of experience developing and producing biopharmaceuticals and vaccines. It is currently expanding its production and looking for qualified workers. ProBioGen has out-licensed its technologies to the TOP 15 global pharma companies, among others, and is therefore very well positioned on the international stage.

    Read more...

    Interview with Prof. Georg N. Duda and Bianca Lemke, Charité and cooperation partner Dr. Lutz Kloke, Cellbricks

    Researchers at the Berlin Institute of Health in the Charité (BIH) have teamed up with colleagues from Cellbricks to develop a 3D printer that can produce a biological wound closure. The development is intended to reach high altitudes and help astronauts treat wounds on site during long space flights. We spoke to the scientists involved, Prof. Georg N. Duda und doctoral candidate Bianca Lemke from the BIH as well as Dr. Lutz Kloke from Cellbricks, about the research.

    Read more...


    Events


    27 April

    Meet us at DMEA 2022 | Reception HealthCapital Berlin-Brandenburg

    » more
     
    11-12 May

    BIONNALE

    » more
     
    20 May

    International clinical trials day (ICTD)

    » more
     
    13 -18 June

    Meet us at BIO International Convention in San Diego, CA

    » more
     


    For more events in the life science region Berlin-Brandenburg click here.


    Business News


    SCIENION celebrates the laying of the foundation stone for new headquarters in Berlin Adlershof

    Together with numerous guests from politics, economics and science, SCIENION GmbH today celebrated the laying of the foundation stone of its new headquarters in Berlin Adlershof. The building complex will be constructed on a space of over 3000m², enabling the company to bundle global activities from a site with sufficient space to pave the way for further growth.

    Read more...

     

    Bayer to strengthen global Pharmaceuticals production network

    By investing into new technologies, automation, and digitalization, Bayer will implement a comprehensive program to substantially upscale its pharmaceutical manufacturing. Over the next three years Bayer will invest around 2 billion Euro into its manufacturing and supply chain capabilities. 

    Read more...

     

    Eckert & Ziegler: Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR

    Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for adrenal diseases, treated the first patient with primary aldosteronism with the Ga-68-based diagnostic PENTIXAFOR as part of the CASTUS study.

    Read more...

     

    Ottobock expands its Western European patient care network

    » more
     

    Lindis Blood Care successfully closes follow-on financing round

    » more
     

    Ada Health extends Series B to $120 million to accelerate rapid growth

    » more
     

    Eckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177 for Clinical Trials

    » more
     

    Science and Technology News


    CHARITÉ RESEARCHERS WIN TWO EUROPEAN RESEARCH COUNCIL’S (ERC) CONSOLIDATOR GRANTS

    How can a heart heal itself? And what determines the sex of a living organism? The European Research Council (ERC) has awarded Consolidator Grants to Dr. Jan Philipp Junker and Dr. Darío Lupiáñez to tackle these questions. Each researcher will receive €2 million over five years for their research.

    Read more...

     

    MDC RESEARCHERS DESCRIBE ALTERATIONS IN THE GUT MICROBIOME THAT PLAY A ROLE IN CARDIOVASCULAR DISEASE DEVELOPMENT

    Changes in the gut microbiome can ultimately lead to cardiovascular disease. Yet some of the alterations appear to normalize in chronic conditions, a team led by ECRC researcher Sofia Forslund reports in Nature Medicine. This finding may have clinical implications.

    Read more...

     

    TECHNISCHE UNIVERSITÄT BERLIN HAS DEVELOPED AN ALGORITHM THAT GENERATES TARGETED MOLECULES BASED ON THEIR DESIRED PROPERTIES

    Whether in medicine, battery research, or materials science, researchers everywhere are seeking innovative substances. In the process, they can often predict the desired chemical and physical properties in great detail, right down to atomic level. However, the range of all potential chemical compounds alone is so vast that it would take years to find the appropriate substance. 

    Read more...

     

    GERMAN INSTITUTE OF HUMAN NUTRITION SHOW HOW BLOOD LIPIDS PROVIDE NEW INSIGHTS INTO THE LINK BETWEEN DIET AND DIABETES AND CARDIOVASCULAR DISEASE

    » more
     

    Charité researchers identified a large number of specific genes which play a key role in the onset and development of schizophrenia

    » more
     

    TWO ERC CONSOLIDATOR GRANTS GO TO MDC RESEARCHERS

    » more
     

    Charité and MDC discover how a bacterial infection causes tissue changes in gastric inflammation

    » more
     

    Max Planck Institute of Molecular Plant Physiology developed a novel strategy to identify protein-molecules that have regulatory functions in stress reduction

    » more
     

    German leading research institutions bring Europe's largest social science panel study to Berlin

    » more
     

    Technology and Cooperation Offers


    A scalable and highly sensitive assay for measuring extracellular NAD+ level in human body fluids

    » more
     


    For more news from the cluster healthcare industries click here.



    Imprint

    The operator and party responsible for content in compliance with § 5 of the German Teleservices Act (TaMG) and in the meaning of the German Press Act:

    Berlin Partner for Business and Technology GmbH
    Fasanenstraße 85 | 10623 Berlin, Germany
    Telephone: +49 30 46302-270
    E-Mail: info (at) healthcapital.de

    Commercial Registry Entry
    Entered in the commercial registry of the Charlottenburg District Court,
    Registration number: HRB 13072 B
    VAT ID: DE 136629780

    CEO:
    Dr. Stefan Franzke

    Acting Executive Chairman:
    Michael Biel

    V. i. S. d. P. Lukas Breitenbach, Head of Corporate Communications Berlin Partner für Wirtschaft und Technologie GmbH
    © 2022 Berlin Partner für Wirtschaft und Technologie GmbH

    Unsubscribe from the newsletter
    The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology. Funded by the federal state of Berlin and the European Regional Development fund through the Investitionsbank Berlin.

    load images load images
    load images